Collegium Pharmaceutical, Inc. (COLL) Stock Price & How to Invest

Last updated November 2026

Short answer

Collegium Pharmaceutical (COLL) is a small specialty drug company that earns most of its profit from older opioid pain brands while it builds an ADHD business with Jornay PM and Azstarys. As of November 20, 2026 the shares closed at about $25.03, down roughly 45% year to date and 43% over the past year, for a market cap near $778 million against about $815 million of trailing revenue.

COLL stock price

As of 2026-11-20, Collegium Pharmaceutical, Inc. (COLL) last closed at $24.72, down 45.2% over the past year. Over the past 52 weeks it has traded between $21.53 and $49.84.

COLL last close
$24.72
1 day
-1.94%
1 month
+7.88%
1 year
-45.24%
52-week range
$21.53 to $49.84
Last close
2026-11-20

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Collegium Pharmaceutical, Inc.'s investor relations page. Walnut is informational, not investment advice.

COLL key stats

At $24.72 on November 20, 2026, Collegium Pharmaceutical, Inc. (COLL) has a market cap of $768M and a P/E of 22.7 on trailing earnings (3.5 on forward earnings).

Market cap
$768M
P/E (trailing)
22.7
P/E (forward)
3.5
EPS (trailing 12 months)
$1.09
Price to book
2.6
Beta
0.73

Market cap, P/E and yield are measured at the $24.72 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Collegium Pharmaceutical, Inc. (COLL)?

The last two weeks for Collegium Pharmaceutical, Inc., as of November 22, 2026: the price move, the next earnings date, and what analysts changed.

  • COLL closed at $24.72 on November 20, 2026, down 2.4% over the past five trading days (from $25.32).
  • On November 16, 2026, Barclays lowered its target to $41.00 from $48.00 (Overweight).

Prices are daily closes from Yahoo Finance. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

What does Collegium Pharmaceutical, Inc. (COLL) do?

Collegium Pharmaceutical, based in Stoughton, Massachusetts, sells branded prescription drugs in the US. It does not discover new molecules; it buys approved brands and runs them with its own sales force. The pain portfolio covers Belbuca (buprenorphine buccal film), Xtampza ER (abuse-deterrent extended-release oxycodone) and the Nucynta franchise (tapentadol). The ADHD side came through two deals: the 2024 purchase of Ironshore, which brought Jornay PM, an evening-dosed methylphenidate, and the May 2026 purchase of Azstarys (serdexmethylphenidate and dexmethylphenidate) from Corium for about $656 million in cash plus up to $135 million in milestones.

Third-quarter 2026 results, reported November 5, showed the two halves pulling in opposite directions. Net product revenue was a record $216.3 million, up about 3% from a year earlier. Jornay PM grew about 24% to $51.9 million and Azstarys added $26.5 million in its first full quarter, so ADHD products passed 36% of revenue. Pain revenue fell about 18% to $138.0 million, led by a 44% drop in Nucynta after generic and authorized-generic entry, while Xtampza ER slipped 9% and Belbuca was close to flat. Adjusted EBITDA fell about 9% to $121.6 million as operating expenses rose with the Azstarys integration, and adjusted EPS was $1.96 against $2.25 a year earlier. GAAP diluted EPS was $0.60. Management reaffirmed 2026 guidance of $825 million to $855 million in revenue and $445 million to $470 million in adjusted EBITDA.

The stock closed at about $25.03 on November 20, 2026, down about 45% year to date and 43% over a year, though up about 9% over the past month, with a 52-week range of roughly $21.43 to $50.79. At that price the market values the equity near $778 million, or roughly 3.3 times trailing adjusted EPS of about $7.67. Debt is a little over $1.08 billion (about $843 million of term loans and $239 million of convertible notes) against about $145 million of cash, so enterprise value is near $1.7 billion and net leverage is about 2 times adjusted EBITDA. The valuation reflects a market that doubts the pain cash flows will last long enough, and that ADHD growth will arrive fast enough, to service the debt and replace the earnings. After the report Barclays cut its price target to $41 from $48 while keeping an Overweight rating, and the eight analysts in Yahoo Finance's count now have a mean target of about $44. Consensus for the fourth quarter is about $222 million of revenue and $1.89 of adjusted EPS.

What's driving Collegium Pharmaceutical, Inc. (COLL)?

1. Jornay PM share gains in ADHD

Jornay PM is the main growth asset. It is taken in the evening so the medicine is working when a child wakes up, a feature no other methylphenidate offers. Third-quarter 2026 revenue was $51.9 million, up about 24%, with prescriptions up about 16% and the prescriber base near 33,000, up 19%. Management puts its share of branded long-acting methylphenidate at about 30%, up 6.5 points in a year, and new-to-brand prescriptions were up 22% in September. Guidance for 2026 is $190 million to $200 million, against $148.9 million in 2025. Adult prescriptions, about 20% of volume, grew about 27%, which points to room beyond the pediatric base.

2. Azstarys as a second ADHD brand

Azstarys, acquired for about $656 million in cash, gives the same roughly 190-person sales force a second product to detail to the same prescribers. The call list has grown to about 27,000 doctors from 21,000 in 2025. Azstarys earned $26.5 million in the September quarter and prescriptions rose nearly 2%, a turn after a 2025 decline under the prior owner. Guidance is $65 million to $75 million for the partial 2026 year, and management expects growth to accelerate in 2027 with consumer and digital campaigns. Its patents run to about 2037, which makes it the longest-lived asset in the portfolio. Up to $135 million in milestone payments could come due if sales and manufacturing goals are met.

3. Cash generation from the pain brands

Pain revenue is shrinking but still produced $138.0 million in the quarter, and these brands carry little research cost. Belbuca, at $57.7 million, has patents running to December 2032, a court win against Alvogen, and gains about 9 million covered lives in the fourth quarter. Xtampza ER, at $45.8 million, moves to an exclusive formulary position with a payer covering about 15 million lives on January 1, 2027. Nucynta pricing after the authorized generic was stable from the second to the third quarter, management said. In October, Collegium paid Grünenthal $17 million to settle a patent suit and end the Nucynta royalty obligation entirely, which lifts the margin on what remains of that franchise.

4. Buybacks, debt paydown and deals

Operating cash flow was $86.5 million in the third quarter, and management lists business development, debt reduction and shareholder returns as its uses. A $50 million accelerated share repurchase began in the quarter and should settle before year-end, with $100 million left on the board authorization that runs through December 2026. Share count has already fallen: about 31.1 million shares were outstanding at the start of November. With net debt near 2 times adjusted EBITDA, the company has room to buy another brand, and analysts on the call asked whether it might sell or spin the pain portfolio. Management declined to comment on any transformational deal.

What are the risks to Collegium Pharmaceutical, Inc. (COLL)?

The largest risk is the pace of pain-portfolio decline. Nucynta revenue fell 44% in a year once generics arrived, and a 2018 settlement allows Teva to sell a generic Belbuca from January 23, 2027 if it has FDA approval. Belbuca was about $222 million of 2025 revenue, so a launch would cut deeply into cash flow. Ascent Pharmaceuticals has also filed to challenge Belbuca's 2032 patent. Xtampza ER faces payer pressure. Opioid exposure brings legal risk: several dozen third-party payors sued Collegium and others in July 2026, alleging Nucynta and Xtampza ER were promoted to encourage continued prescribing, and several state attorneys general have open investigations. ADHD stimulants are Schedule II drugs, so DEA production quotas and shortages can limit supply. The balance sheet carries about $1.08 billion of debt plus a Jornay royalty obligation at about 13.5% effective interest, and cash fell from about $387 million at the end of 2025 to $145 million after the Azstarys purchase. Operating expenses rose 44% in the third quarter, and further acquisitions add integration risk. The stock is small and has been volatile, falling about 17% after the August report and about 45% so far in 2026. Analysts expect revenue of about $848 million in 2027 but adjusted EPS to fall about 5% to roughly $7.08, which reflects the Belbuca generic risk.

What is the Collegium Pharmaceutical, Inc. (COLL) forecast?

8 analysts publish price targets on COLL, averaging $44.00 as of November 2026, or +78.0% against the $24.72 share price on November 20, 2026. The published targets run from $28.00 to $60.00, a wide spread, and the ratings split 7 buy, 1 hold, 0 sell. Over the last six months there have been 0 raises and 7 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full COLL forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is COLL a buy or a sell?

We give no verdict on Collegium Pharmaceutical, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Jornay PM share gains in ADHD. Jornay PM is the main growth asset. The most optimistic published target, $60.00, assumes this works close to its best case.

The case against. The largest risk is the pace of pain-portfolio decline. The most pessimistic target, $28.00, is roughly what COLL is worth if this bites instead.

Read the full bull and bear case on COLL, including what would have to change to break either one. Walnut is not an investment adviser.

How is Collegium Pharmaceutical, Inc. (COLL) valued?

Market cap, P/E and dividend yield at today's price are in the COLL key stats above. The business figures below come from Collegium Pharmaceutical, Inc.'s reported results as of November 2026 and change when it next reports.

  • Revenue (TTM): ~$815 million (+3.3% YoY in Q3)
  • Q3 2026 adjusted EPS: $1.96 vs ~$1.86 consensus
  • Adjusted EBITDA (TTM): ~$467 million
  • Price / adjusted EPS: ~3.3x (~3.5x on 2027 consensus)
  • EV / adjusted EBITDA: ~3.7x
  • Total debt / cash: ~$1.08 billion / ~$145 million

As of November 2026: Figures combine the fourth quarter of 2025 with the first nine months of 2026, at a share price of about $25.03 on November 20, 2026 and about 31.1 million shares outstanding. Adjusted figures exclude large non-cash items, mainly about $55 million a quarter of amortization on acquired drug rights, which is why GAAP diluted EPS for the first nine months of 2026 was only about $0.64 and the trailing GAAP P/E is near 23. A multiple near 3 times adjusted earnings is low for a profitable drug company and shows how much the market discounts the pain brands. The $239 million of convertible notes convert at about $36.56 a share, well above the current price.

Who competes with Collegium Pharmaceutical, Inc. (COLL)?

Branded and generic ADHD medicines

Jornay PM and Azstarys compete with Concerta (J&J Innovative Medicines) and its generics, Takeda's Vyvanse and its lisdexamfetamine generics, Supernus's non-stimulant Qelbree, and Tris Pharma's methylphenidate products. Most ADHD prescriptions are cheap generics, so Collegium's brands depend on payer coverage and on doctors choosing the evening-dosing or prodrug design.

Opioid and non-opioid pain treatments

Belbuca, Xtampza ER and Nucynta compete with generic oxycodone, hydrocodone and buprenorphine from Teva, Hikma and others, with Purdue's OxyContin, and with non-opioid options such as Vertex's Journavx (suzetrigine). Prescriber caution about opioids and generic entry both limit how much these brands can grow.

Specialty pharma consolidators

For investors, the closer peers are acquisitive commercial drug companies: Supernus Pharmaceuticals, ANI Pharmaceuticals, Harmony Biosciences, Pacira BioSciences and Assertio. They also buy late-stage or approved brands and run them through sales forces, and they compete with Collegium for those assets and are valued on cash flow and patent life.

What stocks are similar to Collegium Pharmaceutical, Inc. (COLL)?

Other names that sit close to COLL: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in Collegium Pharmaceutical, Inc. (COLL)

There are three common ways to get COLL exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so COLL sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where COLL fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on Collegium Pharmaceutical, Inc. (COLL)

COLL trades at a low multiple of cash earnings because its pain brands are shrinking and carry generic and litigation risk, while the growing ADHD franchise has to replace that income. The third quarter beat on adjusted EPS ($1.96 against about $1.86 expected) and guidance held, and the shares recovered about 9% in the following month, but analysts expect adjusted EPS to slip from about $7.46 in 2026 to $7.08 in 2027.

More on Collegium Pharmaceutical, Inc. (COLL)

Whether COLL is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is COLL a buy or a sell?, and where the stock could go from here in the COLL stock forecast.

For income investors, whether COLL pays a dividend and how the payout looks is covered in does COLL pay a dividend? And to weigh COLL against a peer, read the full side-by-side comparisons: COLL vs SUPN and COLL vs VERX.

Wondering how COLL fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Collegium Pharmaceutical, Inc.

Ask Walnut's AI anything about COLL and see how it fits what you own.

FAQ

What does Collegium Pharmaceutical do?

+

Collegium is a US specialty pharmaceutical company that buys and sells approved branded drugs instead of running early-stage research. It has two franchises. The pain portfolio includes Belbuca, a buprenorphine film placed against the cheek; Xtampza ER, an abuse-deterrent extended-release oxycodone; and the Nucynta tapentadol products. The ADHD franchise includes Jornay PM, a methylphenidate taken in the evening, and Azstarys, acquired from Corium in May 2026. In the third quarter of 2026 the company reported $216.3 million of net product revenue, with pain products at about 64% and ADHD at about 36%. It sells through a specialty sales force of around 190 representatives in the US and has no meaningful international business.

How did Collegium do in the third quarter of 2026?

+

Revenue grew about 3% to a record $216.3 million, adjusted EBITDA fell about 9% to $121.6 million, and adjusted EPS was $1.96 against $2.25 a year earlier, above the analyst consensus by about 5.6%. GAAP net income was $21.8 million, or $0.60 per diluted share, helped by a tax benefit. Jornay PM revenue grew 24% to $51.9 million and Azstarys added $26.5 million, while pain revenue fell 18% to $138.0 million because Nucynta dropped 44%. Operating cash flow was $86.5 million. The company reaffirmed 2026 guidance of $825 million to $855 million of revenue and $445 million to $470 million of adjusted EBITDA, and the shares rose about 7% on the day of the report.

Why has COLL stock fallen so much?

+

The shares closed at about $25.03 on November 20, 2026, down about 45% year to date and 43% over a year. Three things weighed on them. Nucynta revenue fell sharply once generic and authorized-generic versions arrived, and the shares dropped about 17% after the August report on Nucynta pricing. The Azstarys deal used about $356 million of cash and a $300 million term loan, pushing debt above $1 billion, and higher operating costs mean adjusted EBITDA for 2026 is guided roughly flat with 2025 despite higher revenue. Investors are also weighing a possible generic Belbuca from Teva as early as January 23, 2027. The stock bottomed near $21.43 before the third-quarter report and has since recovered about 9% over the past month.

How has COLL stock performed in 2026?

+

Poorly. As of November 20, 2026 COLL closed at about $25.03, down about 45% year to date and 43% over the past year, against a 52-week range of $21.43 to $50.79. It has rebounded about 9% over the past month after the third-quarter beat. Barclays lowered its target to $41 from $48 on November 13, and the mean analyst target is about $44. Past performance does not predict future returns.

Is Collegium cheap compared with other drug companies?

+

On reported numbers it trades at a low multiple. At about $25.03 a share on November 20, 2026, the market cap is near $778 million, or roughly 3.3 times trailing adjusted EPS of about $7.67 and about 3.7 times trailing adjusted EBITDA on an enterprise-value basis. Many specialty pharma peers trade at high single-digit or low double-digit EBITDA multiples. The discount reflects how much of today's cash flow comes from opioid brands that are losing patent protection or face generic competition, plus the debt load. Whether it is cheap depends on how fast Belbuca, Xtampza ER and Nucynta decline and how much ADHD growth replaces them. GAAP earnings are much lower than adjusted earnings because of amortization on acquired drug rights.

What happens to Belbuca in January 2027?

+

Under a patent settlement, Teva is permitted to launch a generic version of Belbuca from January 23, 2027, provided the FDA has approved its application. Belbuca produced about $222 million in 2025 and $57.7 million in the third quarter of 2026, making it Collegium's largest single product, so generic entry would cut revenue and margin. On the third-quarter call, management said it sees limited risk of near-term generic entry, that Teva still needs FDA approval, and that pricing and wholesaler signals usually appear a month or more before a launch. Other Belbuca patents run to December 2032 and were upheld against Alvogen, and Collegium sued Ascent Pharmaceuticals in July 2026 over a new challenge.

How much debt does Collegium have?

+

At September 30, 2026, Collegium had about $842.5 million of term notes and about $239 million of convertible senior notes due in 2029, a little over $1.08 billion in total, against about $144.8 million of cash and no marketable securities. Management put net debt at about 2 times adjusted EBITDA. The term debt rose from about $571 million at the end of 2025 after a $300 million delayed-draw loan helped fund Azstarys. The convertible notes convert at about $36.56 a share. Collegium also owes a royalty of 9.7% on Jornay PM net sales through March 2032 to former Ironshore lenders, which it accounts for at an effective interest rate of about 13.5%.

Does Collegium face opioid lawsuits?

+

Yes. Several state attorneys general, including Washington, New Hampshire and Maryland, have sent subpoenas or civil investigative demands about opioid sales and marketing, and Collegium settled with Massachusetts in 2021. In July 2026 several dozen third-party payors, such as union health funds, filed a case in Philadelphia against Collegium and many other manufacturers, distributors and pharmacies, alleging Nucynta and Xtampza ER were promoted to encourage continued opioid prescribing. The case was moved to federal court in October, and the company says it will contest it and cannot estimate any loss. These are product and marketing claims, separate from securities litigation. Walgreens is also suing over about $14 million of product-return credits.

How can I invest in Collegium Pharmaceutical?

+

Collegium trades on the Nasdaq under the ticker COLL and can be bought through most US brokerages, many of which allow fractional shares. It pays no dividend; the company returns cash through buybacks, including a $50 million accelerated repurchase in late 2026. It is a small-cap stock, so it appears in small-cap and healthcare index funds only at small weights, and direct ownership is the main way to get meaningful exposure. Some investors place it in a basket with other specialty pharma companies or ADHD-focused names to spread single-company risk around patents and litigation. Walnut can track a COLL position against the S&P 500 and inside a basket. Walnut is not an investment adviser, and this is not a recommendation.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Collegium Pharmaceutical, Inc.'s investor relations page or your broker before making investment decisions.